Search
forLearn
5 / 801 resultslearn Folligen Complex
learn Lactobacillus
learn plant sterol complex
learn Horse placenta extract
Research
5 / 355 results
research New hyaluronan-based biomatrix for 3-D follicle culture yields functionally competent oocytes
A new gel helps grow mature eggs in a lab that can be fertilized and develop further.
research Intraovarian platelet-rich plasma administration could improve blastocyst euploidy rates in women undergoing in vitro fertilization
Platelet-rich plasma may improve embryo genetics in IVF.
research Protein kinase Akt2/PKBβ is involved in blastomere proliferation of preimplantation mouse embryos
Akt2 protein is essential for normal cell division in early mouse embryos.
research Melatonin’s effect on hair follicles in a goat (Capra hircus) animal model
Melatonin improved secondary hair growth in goats but didn't affect primary hair density or litter size.
research OPIS PRZYPADKU RZADKIEGO SAMOTNEGO WŁÓKNISTEGO GUZA KOŚCI KRZYŻOWEJ
Pre-surgical embolization and a two-stage resection improve outcomes for rare sacral tumors.
Community Join
5 / 1000+ resultscommunity Another theory for hair loss: Parasites in gut.
Parasites in the gut may contribute to hair loss by depleting essential nutrients and disrupting hormone balance. An imbalance of hormones, not just DHT, could be a factor in androgenic alopecia.
community Brief update clascoterone phase 3 - Breezula
Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.
community Stemson Therapeutics Human Trial Starting in 2026
Stemson Therapeutics will start human trials for hair cloning in late 2025-2026. Product development is complete, and they are preparing for production and clinical trials.
community Clascoterone full results in July
Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.